Are you checking for any specific mutations in NSCLC that suggest resistance to checkpoint inhibitors?

Topics: Thoracic Malignancies • Medical Oncology

Are there any biomarkers that would affect your decision for first line PD-1 therapy (including but not limited to STK11)?

Answer from: Medical Oncologist at Community Practice

There has been a significant amount of data both published and presented concerning the various genomic markers (mutations) that may predict for response or the absence of response to immune checkpoint inhibitor. However, in clinical practice they are not commonly used as most patients are receiving...

Comments

Medical Oncologist at PINNACLE ONCOLOGY AND HEMATOLOGY
Dr. Dowlati, thank you for the detailed response.&...

Related Questions